How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

722 results for

Panniculitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

601. Childhood acquired lipodystrophy: a retrospective study. (Abstract)

of the follow-up was 4.8 +/- 3.5 years from the time of LD diagnosis. Of patients, 30% had evidence of localized disease (7 of 23), 26% (6 of 23) had localized partial disease, and 44% (10 of 23) had generalized LD. The most common underlying diagnosis was dermatomyositis (78%), alone or in association with other autoimmune diseases (juvenile rheumatoid arthritis 17%). Panniculitis with autoimmunity was noted in 17% of the patients. More than half of the patients had at least one complication attributable

2006 Journal of American Academy of Dermatology

602. Erythema nodosum. (Abstract)

Erythema nodosum. Erythema nodosum is the most frequent clinicopathologic variant of panniculitis. The process is a cutaneous reaction that may be associated with a wide variety of disorders, including infections, sarcoidosis, rheumatologic diseases, inflammatory bowel diseases, medications, autoimmune disorders, pregnancy, and malignancies. Erythema nodosum typically manifest by the sudden onset of symmetrical, tender, erythematous, warm nodules and raised plaques usually located on the lower (...) limbs. Often the lesions are bilaterally distributed. At first, the nodules show a bright red color, but within a few days they become livid red or purplish and, finally, they exhibit a yellow or greenish appearance, taking on the look of a deep bruise. Ulceration is never seen, and the nodules heal without atrophy or scarring. Histopathologically, erythema nodosum is the stereotypical example of a mostly septal panniculitis with no vasculitis. The septa of subcutaneous fat are always thickened

2007 Seminars in Cutaneous Medicine and Surgery

603. Cutaneous polyarteritis nodosa. (Abstract)

arteritis with variable amounts of fibrinoid necrosis and leukocytoclasia, edema and inflammatory cells. The presence of focal panniculitis surrounding the involved artery is characteristic, in contrast with the more diffuse panniculitis usually found in other nodular diseases. Cutaneous PAN has a variable course, with repeated exacerbations. Salicilates relieve the pain in most instances and may be the only treatment required to improve the symptoms in patients with moderate flare-ups. A short course

2007 Seminars in Cutaneous Medicine and Surgery

604. Normal subcutaneous fat, necrosis of adipocytes and classification of the panniculitides. (Abstract)

Normal subcutaneous fat, necrosis of adipocytes and classification of the panniculitides. The panniculitides represent a group of heterogeneous inflammatory diseases that involve the subcutaneous fat. The specific diagnosis of these diseases requires histopathologic study because different panniculitides usually show the same clinical appearance, which consists of erythematous nodules on the lower extremities. However, the histopathologic study of panniculitis is difficult because (...) of an inadequate clinicopathologic correlation and the changing evolutive nature of the lesions. In addition, large scalpel incisional biopsies are required. From histopathologic point of view, all panniculitides are somewhat mixed because the inflammatory infiltrate involves both the septa and lobules. However, nearly always the differential diagnosis between a mostly septal and a mostly lobular panniculitis is straightforward at scanning magnification on the basis of the structures more intensely involved

2007 Seminars in Cutaneous Medicine and Surgery

605. Necrobiosis lipoidica. (Abstract)

Necrobiosis lipoidica. Necrobiosis lipoidica (NL) is a granulomatous condition with a degenerative connective tissue of unknown etiology very often associated with diabetes. Histopathologically, NL involves all of the dermis and, often, the subcutaneous fat produces a septal panniculitis. There are some changes suggesting the diagnosis of NL, and systemic disease should be considered if there is the presence of necrotizing vasculitis in the skin biopsy. Many theories of pathogenesis have been

2007 Seminars in Cutaneous Medicine and Surgery

606. Annular lipoatrophy of the ankles. (Abstract)

Annular lipoatrophy of the ankles. Lipoatrophic panniculitis likely represents a group of disorders characterized by an inflammatory panniculitis followed by lipoatrophy. It occurs locally in a variety of settings and has been reported in the literature under various terms, including annular atrophic connective tissue panniculitis of the ankles, annular and semicircular lipoatrophy, abdominal lipoatrophy, and connective tissue panniculitis. Herein, a case of annular lipoatrophy of the ankles (...) is described in a 6-year-old girl with autoimmune thyroid disease. Histologically, a mixed lobular panniculitis with lipophages was present. This pattern resembles that seen in lipoatrophic panniculitis. After a single, acute episode of an inflammatory process with subsequent lipoatrophy, her skin lesions have stabilized for 2 years requiring no treatment.

2006 Journal of American Academy of Dermatology

607. Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

in the relapsed and/or refractory setting following prior anthracycline therapy. Subtypes of peripheral T-cell lymphomas which meet this criteria will include the following: adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma unspecified, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma, T/null cell, primary systemic type, subcutaneous panniculitis-like T-cell lymphoma, hepatosplenic gamma-delta T-cell lymphoma, and enteropathy-type T-cell lymphoma [33]. Patients with a history

2008 Clinical Trials

608. Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

lymphoma (DLBCL) is allowed if the patient is not eligible for, or refuses, hematopoetic stem cell transplant. Relapsed/refractory nodal, leukemic, and extranodal T cell lymphomas are eligible. Subtypes eligible include anaplastic large cell lymphoma, angioimmunoblastic T cell lymphoma, PTCL-NOS, nasal or disseminated extranodal T/NK lymphoma, enteropathy-associated T cell lymphoma, hepatosplenic gamma/delta T cell lymphoma, subcutaneous panniculitis-like T cell lymphoma, T-prolymphocytic leukemia (...) B and T cell cutaneous lymphoma relapsed or refractory diffuse large B cell lymphoma extranodal T cell lymphomas anaplastic large cell lymphoma angioimmunoblastic T cell lymphoma PTCL-NOS nasal or disseminated extranodal T/NK lymphoma enteropathy-associated T cell lymphoma hepatosplenic gamma/delta T cell lymphoma subcutaneous panniculitis-like T cell lymphoma T-prolymphocytic leukemia adult T-cell leukemia/lymphoma large granular lymphocytic leukemia aggressive NK leukemia Additional relevant

2008 Clinical Trials

609. Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

fungoides Subcutaneous panniculitis-like T-cell lymphoma Nasal T/NK-cell lymphoma Enteropathy-type T-cell lymphoma Hepatosplenic gamma/delta T-cell lymphoma Relapsed or refractory disease, meeting both of the following criteria: Must have been treated with prior cytotoxic chemotherapy and/or monoclonal antibody therapy No standard curative treatment exists Allogeneic bone marrow transplantation is not considered standard curative treatment Evaluable disease (Phase I) Measurable disease, defined as any

2006 Clinical Trials

610. Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

lymphoma Hepatosplenic T cell lymphoma Extranodal peripheral T/NK-cell lymphoma - unspecified Subcutaneous panniculitis T-cell lymphoma Transformed mycosis fungoides Documented progression of disease after at least 1 prior treatment. Patients may not have received experimental therapy as their only prior therapy. Patient has at least 1 biopsy from initial diagnosis or in the relapsed setting to confirm the diagnosis of PTCL. Patient has recovered from the toxic effects of prior therapy. Patients

2006 Clinical Trials

611. A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients

Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Age ≥18 and ≤70 years old. Histological documented high risk T cell lymphoma:extranodal NK/T-cell lymphoma,hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma,angioimmunoblastic T-cell lymphoma,enteropathy-type T-cell lymphoma, peripheral T-cell lymphoma,unspecified. Measurable disease and evaluable lesion. Never previously treated with radiotherapy, chemotherapy or surgery for malignant disease. Normal

2008 Clinical Trials

612. UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

systemic Anaplastic Large Cell Lymphoma (ALCL). Relapsed or refractory mature T-cell lymphoma to include peripheral T-cell lymphoma unspecified and the following "specified" mature T-cell lymphomas: Adult T-cell lymphoma; Extranodal natural killer (NK)/T-cell lymphoma, nasal type; Enteropathy-type T-cell lymphoma; Hepatosplenic T-cell lymphoma; Subcutaneous panniculitis-like T-cell lymphoma; Angioimmunoblastic T-cell lymphoma. All patients should have evaluable or measurable disease on entry to study

2004 Clinical Trials

613. S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Subcutaneous panniculitis-like T-cell lymphoma Angioimmunoblastic T-cell lymphoma Primary cutaneous anaplastic large cell lymphoma (ALCL) ALCL with CD30, ALK, and EMA expression ALCL morphology that fails to express ALK or EMA allowed provided T-cell lineage is confirmed by immunotyping or genetic testing Bidimensionally measurable disease Adequate samples (e.g., core biopsies, especially multiple core biopsies) from the original diagnostic specimen available Needle aspiration or cytology is not considered

2005 Clinical Trials

614. 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Extranodal NK/T cell lymphoma (nasal and nasal type) Enteropathy-type T-cell lymphoma Hepatosplenic T-cell lymphoma Angioimmunoblastic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Chronic lymphocytic leukemia (CLL) Patients with NHL or CLL must meet the following criteria: Ineligible for, or refused potentially curative stem cell transplantation Transformed lymphoma/Richter's transformation, defined as the transformation of low-grade lymphoma, including follicular lymphoma, CLL

2005 Clinical Trials

615. Feasibility Study of a Novel Device for Chronic Wounds

site. However, wounds that are closing by secondary intent after surgical clearance of prior tumor will be allowed in the study. Thick eschar at wound base after debridement. Wound location is not amenable to forming an airtight seal and placement of device. Ulcers due to inflammatory conditions such as pyoderma gangrenosum, rheumatoid arthritis, vasculitis, cryoglobulinemia, necrobiosis lipoidica diabeticorum, lupus or pancreatic panniculitis, cryofibrinogenemia, calcinosis cutis, scleroderma

2008 Clinical Trials

616. The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency

long-term or acute inflammation outside the lung, including connective diseases, panniculitis, or acute infection Unwilling to alter bronchodilator medications for 24 hours prior to scheduled quantitative CT (QCT) scans Musculoskeletal disease that limits exercise by walking Required to take any of the following medications within 48 hours of scheduled lung function testing: dicyclomine (Bentyl), propantheline (Pro-Banthine), mepenzolate (Cantil), methscopolamine (Pamine), and scopolamine

2007 Clinical Trials

617. A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT

Angioimmunoblastic T-cell lymphoma NK/T nasal-type T-cell lymphoma Enteropathy-type T-cell lymphoma Primary systemic, alk-negative anaplastic large cell lymphoma (T-or null phenotype) Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma NB: Patients should not enter the treatment program before confirmation of the histo-pathological diagnosis by the referral center pathologist Age 18-60 years. Patients in the age range 61-67 years may be included in this protocol at discretion

2008 Clinical Trials

618. Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

: Peripheral T-cell lymphoma not otherwise specified (PTCL-U),(IPI >2) Angioimmunoblastic T-cell lymphoma (IPI >2) Non-primary cutaneous Alk-1-negative anaplastic large cell lymphoma Extranodal NK/T lymphoma (Excluding stage I/II nasal disease) Blastic NK cell lymphoma Enteropathy type T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Hepatosplenic T-cell lymphoma Measurable or assessable disease is not required. Age >18 and < 70 years Previously untreated or 1 prior cycle of chemotherapy

2008 Clinical Trials

619. Alemtuzumab and CHOP in T-cell Lymphoma

Enteropathy-type T cell lymphoma Subcutaneous panniculitis-like T-NHL (gamma-delta T-cell lymphoma) Hepatosplenic T-cell lymphoma Extranodal NK/T cell lymphoma, nasal type Age 18-60 years at time of randomization Life expectancy of 3 months or longer ECOG performance status (PS) 0, 1 or 2 at the time of randomization. However, PS 3 will be acceptable if lymphoma-related. Measurable disease (defined as at least one lesion with two measurable perpendicular diameters of which at least one should be >= 15 mm

2008 Clinical Trials

620. Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

macroglobulinemia) Central Nervous System (CNS) lymphoma Post-transplant lymphoproliferative disorder Mycosis fungoides/Sezary syndrome Hodgkin's lymphoma Primary effusion lymphoma Blastic Natural Killer(NK)-cell lymphoma Adult T-cell leukemia/lymphoma Nasal type extranodal NK/T-cell lymphoma Enteropathy type T-cell lymphoma Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Angioimmunoblastic T-cell lymphoma NOTE: *Biopsies performed < 6 months prior to study entry are allowed; biopsy

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>